MedTech News
.................... by Andrew Celentano

Avulux lands FDA de novo classification for light-sensitive migraine lenses
Avulux’s lens technology uses a optical filters to block up to 97% of blue, amber, and red light while letting soothing green light through.

Olympus launches new flexible-tip videoscope
Olympus Corporation has announced the launch of the ENDOEYE FLEX 3D flexible-tip videoscope, compatible with the VISERA ELITE III surgical imaging platform to support more efficient, high-quality endoscopic surgery.

Dual therapy activates immune defenses while damaging lung cancer DNA
A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while also stimulating the body’s immune system to combat the disease. The research is published in the journal Cell Reports Medicine.

Altered ribosomes help explain how an enzyme fuels tumor growth
A new Northwestern Medicine study has identified a previously unknown mechanism by which an enzyme promotes cancer cell proliferation, establishing it as a promising therapeutic target for cancer, according to findings published in Nature Communications.

Researchers uncover brain-network dynamics in schizophrenia
Researchers at Georgia State University have identified a previously unknown aspect of schizophrenia that offers a new way to understand how the disorder affects large-scale brain coordination. In a new study, published in the journal Translational Psychiatry, researchers introduced a method for measuring how brain networks maintain balanced activity and recover when that balance is disrupted.

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer’s Disease Pathology in Both Primary and Specialty Care Settings
BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer’s disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings

Roche’s pTau217 single-biomarker Alzheimer’s blood test lands FDA approval
FDA clearance for Roche’s pTau217 follows the blood-based test’s receipt of a European CE mark in May 2026.

Smart probiotics can sense high blood sugar and release GLP-1 on demand
For people living with diabetes, managing blood sugar can mean constantly watching the clock, keeping meals and medications on schedule and staying alert to changes in glucose levels. While little can be done about timed meals, researchers have developed a biological system that detects rising blood sugar levels and automatically responds by releasing medication to bring glucose back down.